Latest News

STAT Plus: Pharmalittle: Biogen reaches deal with U.K. for its SMA drug; did Gilead thwart generic competition to an HIV pill?

Top of the morning to you. Another busy day is unfolding here on the Pharmalot campus, where we are mulling over our cluttered calendar and plotting our next moves. No doubt, you can relate. After all, this is only the middle of the week and there is so much to be done. This calls, as you may imagine, for a hot cup of stimulation. We are sticking with the caramel cream, for no particular reason. Feel free to join us. Meanwhile, here are some tidbits. The world is a busy place, yes? Hope you make your way today. …

The National Health Service in England reached a deal with Biogen (BIIB) for the Spinraza spinal muscle atrophy treatment, Reuters writes. Under the so-called managed access agreement, Biogen will provide funding for a limited time and collect effectiveness data; however, NHS England did not disclose the price it will pay for the drug. Spinraza has a U.S. list price of $750,000 for the first year and $375,000 annually thereafter. Initially, a U.K. agency declared the drug was not cost-effective, despite a discount from Biogen.

Continue to STAT Plus to read the full story…

Source link

Related posts

Seven key heart health measures may help predict future risk of CVD


Peptide isolated from spirulina extract may counteract arterial hypertension


Combination of drugs may combat deadly drug-resistant fungus


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy